| 1 | Cancer Testis Antigen Expression Correlates With Immune Activation and Survival in Small Bowel Neuroendocrine Tumors. (Ayabe RI, Seo YD, Melendez B, Fields BC, Diggs LP, Lazcano R, Singh BB, Wani K, Ingram D, Johnson S, Chelvanambi M, Hudgens C, Hernandez SD, Ajami NJ, Wargo JA, Lazar AJ, Knafl M, Woodman S, Halperin DM, Estrella JS, Maxwell JE) JCO Precis Oncol 2025 Jul;9:e2500107 |
| 2 | Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. (Perez K, Del Rivero J, Kennedy EB, Basu S, Chauhan A, Connolly HM, Dasari AN, Gangi A, Clarke CN, Hallet J, Howe JR, Grady E, Ivanidze J, Mittra ES, White SB, Raj NP, Vijayvergia N, Lewis MA, Chan JA, Kunz PL, Mailman J, Arshad J, Soares HP, Singh S, Chandrasekharan C, Soulen MC, Janson ET, Halfdanarson TR, Strosberg JR, Bergsland EK) JCO Oncol Pract 2026 Jan;22(1):19-35 12 Citations |
| 1 | The Landmark Series: Surgical Management of Functioning and Non-Functioning Pancreatic Neuroendocrine Tumors. (Tobias J, Clarke CN, Gangi A, Keutgen XM) Ann Surg Oncol 2025 Jul;32(7):4720-4728 2 Citations |
| 1 | Current Status of Immunotherapy in Management of Small Bowel Neuroendocrine Tumors. (Fields BC, Ayabe RI, Seo YD, Maxwell JE, Halperin DM) Curr Oncol Rep 2024 Nov;26(11):1530-1542 2 Citations |
| 2 | Impact of Regional Metastasis on Survival for Patients with Nonfunctional Pancreatic Neuroendocrine Tumors: A Systematic Review. (Clarke CN, Ward E, Henry V, Nimmer K, Phan A, Evans DB) Ann Surg Oncol 2024 Aug;31(8):4976-4985 3 Citations |
| 1 | Evolution of Surgical Management and Outcomes of Neuroendocrine Tumor Liver Metastases. (Bello RJ, Clarke CN) Ann Surg Oncol 2024 Apr;31(4):2192-2193 |
| 1 | Making progress against rare cancers: A case study on neuroendocrine tumors. (O'Rorke M, Chrischilles E, NET‐PRO Study Investigators) Cancer 2024 May 01;130(9):1568-1574 5 Citations |
| 1 | ASO Practice Guidelines Series: Surgical Management of Gastrointestinal (Midgut) Neuroendocrine Neoplasms. (Hallet J, Clarke CN) Ann Surg Oncol 2024 Mar;31(3):1704-1713 10 Citations |
| 1 | Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. (Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, Basu S, Chauhan A, Dasari AN, Bellizzi AM, Gangi A, Grady E, Howe JR, Ivanidze J, Lewis M, Mailman J, Raj N, Soares HP, Soulen MC, White SB, Chan JA, Kunz PL, Singh S, Halfdanarson TR, Strosberg JR, Bergsland EK) J Clin Oncol 2023 Nov 10;41(32):5049-5067 84 Citations |
| 1 | The Global Reading Room: A Patient With Neuroendocrine Liver Metastases After Pancreaticoduodenectomy. (Braat AJAT, Kim HC, Vogl TJ, White SB) AJR Am J Roentgenol 2024 Jun;222(6):e2330113 1 Citation |
| 1 | Multi-institutional assessment of the prevalence of neuroendocrine tumors in children undergoing laparoscopic appendectomy for acute appendicitis in the United States. (Zeineddin S, Aldrink JH, Bering J, Hoyt DW, Kastenberg ZJ, Brungardt J, Dasgupta R, Rinehardt HN, Malek MM, Ziogas IA, Roach JP, Craig BT, Rothstein DH, Lautz TB) Pediatr Blood Cancer 2023 Nov;70(11):e30620 10 Citations |
| 3 | Primary Breast Neuroendocrine Tumors: An Analysis of the National Cancer Database. (Martinez EO, Jorns JM, Kong AL, Kijak J, Lee WY, Huang CC, Cortina CS) Ann Surg Oncol 2022 Oct;29(10):6339-6346 16 Citations |
| 1 | Neuroendocrine Tumors: a Relevant Clinical Update. (Rizen EN, Phan AT) Curr Oncol Rep 2022 Jun;24(6):703-714 28 Citations |
| 1 | A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort. (Patel SP, Mayerson E, Chae YK, Strosberg J, Wang J, Konda B, Hayward J, McLeod CM, Chen HX, Sharon E, Othus M, Ryan CW, Plets M, Blanke CD, Kurzrock R) Cancer 2021 Sep 01;127(17):3194-3201 102 Citations |
| 1 | Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. (Baca SC, Takeda DY, Seo JH, Hwang J, Ku SY, Arafeh R, Arnoff T, Agarwal S, Bell C, O'Connor E, Qiu X, Alaiwi SA, Corona RI, Fonseca MAS, Giambartolomei C, Cejas P, Lim K, He M, Sheahan A, Nassar A, Berchuck JE, Brown L, Nguyen HM, Coleman IM, Kaipainen A, De Sarkar N, Nelson PS, Morrissey C, Korthauer K, Pomerantz MM, Ellis L, Pasaniuc B, Lawrenson K, Kelly K, Zoubeidi A, Hahn WC, Beltran H, Long HW, Brown M, Corey E, Freedman ML) Nat Commun 2021 Mar 30;12(1):1979 123 Citations |
| 1 | Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. (Caplin ME, Pavel M, Phan AT, Ćwikła JB, Sedláčková E, Thanh XT, Wolin EM, Ruszniewski P, CLARINET Investigators) Endocrine 2021 Feb;71(2):502-513 77 Citations |
| 1 | The Chicago Consensus on Peritoneal Surface Malignancies: Management of Neuroendocrine Tumors. (Chicago Consensus Working Group) Ann Surg Oncol 2020 Jun;27(6):1788-1792 20 Citations |
| 1 | The Chicago Consensus on peritoneal surface malignancies: Management of neuroendocrine tumors. (Chicago Consensus Working Group) Cancer 2020 Jun 01;126(11):2561-2565 10 Citations |
| 1 | Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors. (Grenader T, Pavel ME, Ruszniewski PB, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Truong Thanh XM, Caplin ME, CLARINET Study Group) Anticancer Drugs 2020 Mar;31(3):216-222 6 Citations |
| 1 | A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. (Patel SP, Othus M, Chae YK, Giles FJ, Hansel DE, Singh PP, Fontaine A, Shah MH, Kasi A, Baghdadi TA, Matrana M, Gatalica Z, Korn WM, Hayward J, McLeod C, Chen HX, Sharon E, Mayerson E, Ryan CW, Plets M, Blanke CD, Kurzrock R) Clin Cancer Res 2020 May 15;26(10):2290-2296 300 Citations |
| 1 | RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression. (Li Y, Xie N, Chen R, Lee AR, Lovnicki J, Morrison EA, Fazli L, Zhang Q, Musselman CA, Wang Y, Huang J, Gleave ME, Collins C, Dong X) Eur Urol 2019 Aug;76(2):157-166 25 Citations |
| 1 | Pixel-to-Pixel Learning With Weak Supervision for Single-Stage Nucleus Recognition in Ki67 Images. (Xing F, Cornish TC, Bennett T, Ghosh D, Yang L) IEEE Trans Biomed Eng 2019 Nov;66(11):3088-3097 49 Citations |
| 1 | Natural History and Treatment Trends in Pancreatic Cancer Subtypes. (Pokrzywa CJ, Abbott DE, Matkowskyj KA, Ronnekleiv-Kelly SM, Winslow ER, Weber SM, Fisher AV) J Gastrointest Surg 2019 Apr;23(4):768-778 31 Citations |
| 1 | Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors. (Pavel ME, Phan AT, Wolin EM, Mirakhur B, Liyanage N, Pitman Lowenthal S, Fisher GA Jr, Vinik AI, CLARINET Study Investigators) Oncologist 2019 Apr;24(4):463-474 15 Citations |
| 1 | Management of Neuroendocrine Tumors in the Twenty-First Century. (Ioachimescu AG) Endocrinol Metab Clin North Am 2018 Sep;47(3):xiii-xiv 4 Citations |
| 1 | Transformation of a non-secretory neuroendocrine tumor to insulinoma after treatment with Sunitinib: A case report and review of the literature. (Clover T, Abdelkader A, Guru Murthy GS) J Oncol Pharm Pract 2019 Sep;25(6):1516-1519 5 Citations |
| 1 | Incidental Neuroendocrine Tumor Discovered After Total Pancreatectomy Intended for Islet Autotransplantation: Important Considerations for Surgical Decision-Making. (Serrano OK, Peterson KJ, Mettler T, Wilhelm JJ, Bellin MD, Beilman GJ, Trikudanathan G, Pruett TL, Dunn TB) Pancreas 2018 Jul;47(6):778-782 4 Citations |
| 1 | Emerging treatment options for patients with gastroenteropancreatic neuroendocrine tumors. (Phan AT) Clin Adv Hematol Oncol 2017 Apr;15 Suppl 4(4):10-14 1 Citation |
| 1 | Recent advances in the management of gastroenteropancreatic neuroendocrine tumors: Discussion. (Iyer R, Phan AT, Boudreaux JP) Clin Adv Hematol Oncol 2017 Apr;15 Suppl 4(4):18-19 |
| 1 | Recent advances in the management of gastroenteropancreatic neuroendocrine tumors: insights from the 2017 ASCO Gastrointestinal Cancers Symposium. (Iyer R, Phan AT, Boudreaux JP) Clin Adv Hematol Oncol 2017 Apr;15 Suppl 4(4):1-24 4 Citations |
| 1 | Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study. (Halle MK, Ojesina AI, Engerud H, Woie K, Tangen IL, Holst F, Høivik E, Kusonmano K, Haldorsen IS, Vintermyr OK, Trovik J, Bertelsen BI, Salvesen HB, Krakstad C) Am J Obstet Gynecol 2017 Oct;217(4):432.e1-432.e17 48 Citations |
| 1 | Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences. (Ryan P, Phan AT, Adelman DT, Iwasaki M) Clin J Oncol Nurs 2016 Dec 01;20(6):E139-E146 8 Citations |
| 1 | The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors. (Phan AT, Dave B) Cancer Med 2016 Oct;5(10):2953-2964 14 Citations |
| 1 | Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival. (Chen JX, Rose S, White SB, El-Haddad G, Fidelman N, Yarmohammadi H, Hwang W, Sze DY, Kothary N, Stashek K, Wileyto EP, Salem R, Metz DC, Soulen MC) Cardiovasc Intervent Radiol 2017 Jan;40(1):69-80 97 Citations |
| 1 | Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. (Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Gomez-Panzani E, Ruszniewski P, CLARINET Investigators) Endocr Relat Cancer 2016 Mar;23(3):191-9 226 Citations |
| 1 | New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors. (Phan AT, Kunz PL, Reidy-Lagunes DL) Clin Adv Hematol Oncol 2015 May;13(5 Suppl 5):1-18; quiz 1 p following 18 8 Citations |
| 1 | Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion. (de Baere T, Arai Y, Lencioni R, Geschwind JF, Rilling W, Salem R, Matsui O, Soulen MC) Cardiovasc Intervent Radiol 2016 Mar;39(3):334-43 246 Citations |
| 1 | Eliminating the Residual Negative Pressure in the Endoscopic Ultrasound Aspirating Needle Enhances Cytology Yield of Pancreas Masses. (Aadam AA, Oh YS, Shidham VB, Khan A, Hunt B, Rao N, Zhang Y, Tarima S, Dua KS) Dig Dis Sci 2016 Mar;61(3):890-9 14 Citations |
| 1 | Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. (Phan AT, Halperin DM, Chan JA, Fogelman DR, Hess KR, Malinowski P, Regan E, Ng CS, Yao JC, Kulke MH) Lancet Oncol 2015 Jun;16(6):695-703 119 Citations |
| 1 | Advances in the treatment of gastroenteropancreatic neuroendocrine tumors. (Phan AT) Clin Adv Hematol Oncol 2014 Dec;12(12 Suppl 19):3-5 2 Citations |
| 1 | Liver metastases of small intestine neuroendocrine tumors: Ki-67 heterogeneity and World Health Organization grade discordance with primary tumors. (Shi C, Gonzalez RS, Zhao Z, Koyama T, Cornish TC, Hande KR, Walker R, Sandler M, Berlin J, Liu EH) Am J Clin Pathol 2015 Mar;143(3):398-404 76 Citations |
| 1 | Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well-differentiated neuroendocrine tumors. (Yao JC, Phan AT, Hess K, Fogelman D, Jacobs C, Dagohoy C, Leary C, Xie K, Ng CS) Pancreas 2015 Mar;44(2):190-7 58 Citations |
| 1 | Lanreotide in metastatic enteropancreatic neuroendocrine tumors. (Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P, CLARINET Investigators) N Engl J Med 2014 Jul 17;371(3):224-33 1289 Citations |
| 1 | Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. (Francis JM, Kiezun A, Ramos AH, Serra S, Pedamallu CS, Qian ZR, Banck MS, Kanwar R, Kulkarni AA, Karpathakis A, Manzo V, Contractor T, Philips J, Nickerson E, Pho N, Hooshmand SM, Brais LK, Lawrence MS, Pugh T, McKenna A, Sivachenko A, Cibulskis K, Carter SL, Ojesina AI, Freeman S, Jones RT, Voet D, Saksena G, Auclair D, Onofrio R, Shefler E, Sougnez C, Grimsby J, Green L, Lennon N, Meyer T, Caplin M, Chung DC, Beutler AS, Ogino S, Thirlwell C, Shivdasani R, Asa SL, Harris CR, Getz G, Kulke M, Meyerson M) Nat Genet 2013 Dec;45(12):1483-6 292 Citations |
| 1 | Autophagy sensitivity of neuroendocrine lung tumor cells. (Hong SK, Kim JH, Starenki D, Park JI) Int J Oncol 2013 Dec;43(6):2031-8 12 Citations |
| 1 | Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate. (McCall CM, Shi C, Cornish TC, Klimstra DS, Tang LH, Basturk O, Mun LJ, Ellison TA, Wolfgang CL, Choti MA, Schulick RD, Edil BH, Hruban RH) Am J Surg Pathol 2013 Nov;37(11):1671-7 152 Citations |
| 1 | A single institution's 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram. (Ellison TA, Wolfgang CL, Shi C, Cameron JL, Murakami P, Mun LJ, Singhi AD, Cornish TC, Olino K, Meriden Z, Choti M, Diaz LA, Pawlik TM, Schulick RD, Hruban RH, Edil BH) Ann Surg 2014 Feb;259(2):204-12 |
| 1 | Consensus guidelines for the management and treatment of neuroendocrine tumors. (Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK, Klimstra DS, Kulke MH, Liu EH, Metz DC, Phan AT, Sippel RS, Strosberg JR, Yao JC, North American Neuroendocrine Tumor Society) Pancreas 2013 May;42(4):557-77 529 Citations |
| 1 | Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience. (Yao JC, Phan AT, Jehl V, Shah G, Meric-Bernstam F) Cancer Res 2013 Mar 01;73(5):1449-53 71 Citations |
| 1 | Clinical burden of illness in patients with neuroendocrine tumors. (Hess GP, Chen CC, Liu Z, Yao JC, Phan AT, Hill JW) Pancreas 2012 Oct;41(7):1058-62 13 Citations |
| 1 | Metastatic pancreatic neuroendocrine tumors (pNET): placing current findings into perspective. (Phan AT) Cancer Treat Rev 2013 Feb;39(1):3-9 7 Citations |
| 1 | Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. (Beaumont JL, Cella D, Phan AT, Choi S, Liu Z, Yao JC) Pancreas 2012 Apr;41(3):461-6 158 Citations |
| 1 | New strategies for advanced neuroendocrine tumors in the era of targeted therapy. (Dong M, Phan AT, Yao JC) Clin Cancer Res 2012 Apr 01;18(7):1830-6 50 Citations |
| 1 | Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. (Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St Peter J, Cherfi A, Öberg KE) J Clin Endocrinol Metab 2011 Dec;96(12):3741-9 201 Citations |
| 1 | Metastatic neuroendocrine tumor found on screening mammogram. (Amin AL, Kong AL) WMJ 2011 Jun;110(3):140-3; quiz 145 14 Citations |
| 1 | Radiofrequency ablation of neuroendocrine hepatic metastasis. (Gamblin TC, Christians K, Pappas SG) Surg Oncol Clin N Am 2011 Apr;20(2):273-9, vii-viii 29 Citations |
| 1 | NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). (Phan AT, Oberg K, Choi J, Harrison LH Jr, Hassan MM, Strosberg JR, Krenning EP, Kocha W, Woltering EA, Maples WJ, North American Neuroendocrine Tumor Society (NANETS)) Pancreas 2010 Aug;39(6):784-98 169 Citations |
| 1 | Small pancreatic and periampullary neuroendocrine tumors: resect or enucleate? (Pitt SC, Pitt HA, Baker MS, Christians K, Touzios JG, Kiely JM, Weber SM, Wilson SD, Howard TJ, Talamonti MS, Rikkers LF) J Gastrointest Surg 2009 Sep;13(9):1692-8 114 Citations |
| 1 | Neuroendocrine tumors: novel approaches in the age of targeted therapy. (Phan AT, Yao JC) Oncology (Williston Park) 2008 Dec;22(14):1617-23; discussion 1623-4, 1629 12 Citations |
| 2 | Treatment options for metastatic neuroendocrine tumors. (Phan AT, Yao JC, Evans DB) Surgery 2008 Dec;144(6):895-8 5 Citations |
| 1 | Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. (Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F) J Clin Oncol 2008 Sep 10;26(26):4311-8 576 Citations |
| 2 | Hepatic neuroendocrine metastases: chemo- or bland embolization? (Pitt SC, Knuth J, Keily JM, McDermott JC, Weber SM, Chen H, Rilling WS, Quebbeman EJ, Agarwal DM, Pitt HA) J Gastrointest Surg 2008 Nov;12(11):1951-60 93 Citations |
| 1 | One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. (Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB) J Clin Oncol 2008 Jun 20;26(18):3063-72 4050 Citations |
| 1 | Abdominal visceral lesions in von Hippel-Lindau disease: incidence and clinical behavior of pancreatic and adrenal lesions at a single center. (Delman KA, Shapiro SE, Jonasch EW, Lee JE, Curley SA, Evans DB, Perrier ND) World J Surg 2006 May;30(5):665-9 38 Citations |
| 1 | Surgical treatment of non-functioning pancreatic islet cell tumors. (Kouvaraki MA, Solorzano CC, Shapiro SE, Yao JC, Perrier ND, Lee JE, Evans DB) J Surg Oncol 2005 Mar 01;89(3):170-85 65 Citations |
| 1 | Advances in the diagnosis and treatment of gastrointestinal neuroendocrine tumors. (Lee JE, Evans DB) Cancer Treat Res 1997;90:227-38 5 Citations |
